Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPT | P10636 | 1/20 | 0.57 |
| ▸ | APP | P05067 | 1/20 | 0.54 |
| ▸ | FFAR1 | O14842 | 1/20 | 0.53 |
| ▸ | ERN1 | O75460 | 1/20 | 0.49 |
| ▸ | GRM5 | P41594 | 3/20 | 0.49 |
| ▸ | GRM4 | Q14833 | 1/20 | 0.47 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30214468 | 0.84 | FFAR1 (0.58) | APPFFAR1GRM5GRM4KCNH2 | |
| SCHEMBL1809895 | 0.84 | FFAR1 (0.58) | APPFFAR1GRM5GRM4KCNH2 | |
| Hydrochloric Acid SCHEMBL19668206 | 0.82 | FFAR1 (0.57) | APPFFAR1GRM5GRM4KCNH2 | |
| SCHEMBL352291 | 0.81 | GRM5 (0.65) | GRM5KCNH2 | |
| SCHEMBL5569770 | 0.81 | GRM5 (0.53) | FFAR1ERN1GRM5KCNH2 | |
| SCHEMBL30214469 | 0.81 | FFAR1 (0.53) | FFAR1ERN1GRM5KCNH2 | |
| SCHEMBL4750207 | 0.81 | FFAR1 (0.53) | FFAR1ERN1GRM5KCNH2 | |
| SCHEMBL14061855 | 0.81 | GRM5 (0.53) | FFAR1ERN1GRM5KCNH2 | |
| SCHEMBL28950042 | 0.81 | GRM5 (0.56) | FFAR1ERN1GRM5KCNH2 | |
| SCHEMBL2809759 | 0.80 | ERN1 (0.49) | ERN1GRM5 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20140315857-A1 | N- (4 -QUINOLINYLMETHYL) SULFONAMIDE DERIVATIVES AND THEIR USE AS ANTHELMINTICS | E. I. DUPONT DE NEMOURS AND COMPANY | 2014-10-23 | — | — | US | disclosed |
| EP-2785694-A1 | N- (4 -QUINOLINYLMETHYL) SULFONAMIDE DERIVATIVES AND THEIR USE AS ANTHELMINTICS | E. I. Du Pont de Nemours and Company (US) | 2014-10-08 | — | — | EP | disclosed |
| WO-2013081783-A1 | N- (4 -QUINOLINYLMETHYL) SULFONAMIDE DERIVATIVES AND THEIR USE AS ANTHELMINTICS | E. I. DU PONT DE NEMOURS AND COMPANY (US) | 2013-06-06 | — | — | WO | disclosed |
| US-20100298343-A1 | 5-LIPOXYGENASE-ACTIVATING PROTEIN (FLAP) INHIBITORS | AMIRA PHARMACEUTICALS, INC. | 2010-11-25 | — | — | US | disclosed |
| US-20100298343-A1 | 5-LIPOXYGENASE-ACTIVATING PROTEIN (FLAP) INHIBITORS | AMIRA PHARMACEUTICALS, INC. | 2010-11-25 | — | — | US | disclosed |
| US-20100298343-A1 | 5-LIPOXYGENASE-ACTIVATING PROTEIN (FLAP) INHIBITORS | AMIRA PHARMACEUTICALS, INC. | 2010-11-25 | — | — | US | disclosed |
| EP-2207547-A2 | 5-LIPOXYGENASE-ACTIVATING PROTEIN (FLAP) INHIBITORS | Amira Pharmaceuticals, Inc. (US) | 2010-07-21 | — | — | EP | disclosed |
| WO-2009045700-A2 | 5-LIPOXYGENASE-ACTIVATING PROTEIN (FLAP) INHIBITORS | AMIRA PHARMACEUTICALS, INC. (US) | 2009-04-09 | — | — | WO | disclosed |
| WO-2009045700-A2 | 5-LIPOXYGENASE-ACTIVATING PROTEIN (FLAP) INHIBITORS | AMIRA PHARMACEUTICALS, INC. (US) | 2009-04-09 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100298343-A1 | 5-LIPOXYGENASE-ACTIVATING PROTEIN (FLAP) INHIBITORS | ALOX5, ALOX15B, ALOX15 | MAPT 4848/4885APP 3898/4885FFAR1 661/4885 |
| US-20140315857-A1 | N- (4 -QUINOLINYLMETHYL) SULFONAMIDE DERIVATIVES AND THEIR USE AS ANTHELMINTICS | NQO2, SQOR, QSOX1 | MAPT 4694/4885APP 4355/4885FFAR1 2775/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.